secwatch / observer
8-K filed February 15, 2024, 6:59 PM ET ticker PACB CIK 0001299130
earnings confidence high sentiment neutral materiality 0.75

PacBio Q4 rev $58.4M (+113% YoY) but GAAP gross margin drops to 16%; FY rev $200.5M

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

2023-FY EPS reported -$1.21 revenue$200,521,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported fiscal year ended December 31, 2023 results: revenue Revenue of $200.5 million, net income Net loss for 2023 was $306.7 million, EPS Net loss per share for 2023 was $1.21.

Period
fiscal year ended December 31, 2023
Revenue
Revenue of $200.5 million
Net income
Net loss for 2023 was $306.7 million
EPS
Net loss per share for 2023 was $1.21
Result
reported results
Exact text from the filing
Fiscal year 2023 results • Revenue of $200.5 million, a 56% increase compared with $128.3 million in the prior-year period. • Instrument revenue of $120.5 million compared with $48.7 million in the prior-year period. • Consumables revenue of $63.4 million compared with $60.0 million in the prior-year period. • Service and other revenue of $16.6 million compared with $19.6 million in the prior-year period. Gross profit for 2023 was $52.8 million, representing an 8% increase compared with $49.0 million for 2022 and a gross margin of 26% in 2023 compared to 38% for 2022. Non-GAAP gross profit for 2023 was $54.9 million and represented a non-GAAP gross margin of 27% in 2023, compared to a non-GAAP gross profit of $49.8 million in 2022, which represented a non-GAAP gross margin of 39% (see accompanying tables for reconciliations of GAAP and non-GAAP measures). Operating expenses totaled $387.2 million for 2023, compared to $356.2 million for 2022. Non-GAAP operating expenses totaled $354.8
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported fourth fiscal quarter ended December 31, 2023 results: revenue Revenue of $58.4 million, net income Net loss for the fourth quarter of 2023 was $82.0 million, EPS Net loss per share for the fourth quarter of 2023 was $0.31.

Period
fourth fiscal quarter ended December 31, 2023
Revenue
Revenue of $58.4 million
Net income
Net loss for the fourth quarter of 2023 was $82.0 million
EPS
Net loss per share for the fourth quarter of 2023 was $0.31
Result
reported results
Exact text from the filing
Fourth quarter results • Revenue of $58.4 million, a 113% increase compared with $27.4 million in the prior-year period. • Instrument revenue of $35.1 million compared with $6.1 million in the prior-year period. • Consumables revenue of $18.9 million compared with $16.7 million in the prior-year period. • Service and other revenue of $4.4 million compared with $4.6 million in the prior-year period. • Shipped 44 Revio TM sequencing systems in the fourth quarter of 2023, bringing the installed base as of December 31, 2023, to 173 systems. Gross profit for the fourth quarter of 2023 was $9.6 million, representing an 86% increase compared with $5.1 million for the fourth quarter of 2022 and a gross margin of 16% in the fourth quarter of 2023 compared to 19% for the fourth quarter of 2022. Non-GAAP gross profit for the fourth quarter of 2023 was $11.1 million and represented a non-GAAP gross margin of 19% in the fourth quarter of 2023, compared to a non-GAAP gross profit of $5.3 million in
View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filing history →

Source: SEC EDGAR
accession 0001299130-24-000014
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.